BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 31389715)

  • 1. Differential Diagnosis of Epithelioid Malignant Mesothelioma With Lung and Breast Pleural Metastasis: A Systematic Review Compared With a Standardized Panel of Antibodies-A New Proposal That May Influence Pathologic Practice.
    Le Stang N; Burke L; Blaizot G; Gibbs AR; Lebailly P; Clin B; Girard N; Galateau-Sallé F;
    Arch Pathol Lab Med; 2020 Apr; 144(4):446-456. PubMed ID: 31389715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
    Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
    Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma.
    Klebe S; Swalling A; Jonavicius L; Henderson DW
    J Clin Pathol; 2016 Feb; 69(2):136-41. PubMed ID: 26281863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calretinin-expressing lung adenocarcinoma: Distinct characteristics of advanced stages, smoker-type features, and rare expression of other mesothelial markers are useful to differentiate epithelioid mesothelioma.
    Matsuda M; Ninomiya H; Wakejima R; Inamura K; Okumura S; Mun M; Kitagawa M; Ishikawa Y
    Pathol Res Pract; 2020 Mar; 216(3):152817. PubMed ID: 32008868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.
    Husain AN; Colby T; Ordonez N; Krausz T; Attanoos R; Beasley MB; Borczuk AC; Butnor K; Cagle PT; Chirieac LR; Churg A; Dacic S; Fraire A; Galateau-Salle F; Gibbs A; Gown A; Hammar S; Litzky L; Marchevsky AM; Nicholson AG; Roggli V; Travis WD; Wick M;
    Arch Pathol Lab Med; 2013 May; 137(5):647-67. PubMed ID: 22929121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data.
    King JE; Thatcher N; Pickering CA; Hasleton PS
    Histopathology; 2006 Feb; 48(3):223-32. PubMed ID: 16430468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.
    Marchevsky AM; LeStang N; Hiroshima K; Pelosi G; Attanoos R; Churg A; Chirieac L; Dacic S; Husain A; Khoor A; Klebe S; Lantuejoul S; Roggli V; Vignaud JM; Weynard B; Sauter J; Henderson D; Nabeshima K; Galateau-Salle F
    Hum Pathol; 2017 Sep; 67():160-168. PubMed ID: 28782639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study.
    Ordóñez NG; Sahin AA
    Hum Pathol; 2014 Jul; 45(7):1529-40. PubMed ID: 24816068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant Cytokeratin 20 Reactivity in Epithelioid Malignant Mesothelioma: A Case Report.
    Manur R; Lamzabi I
    Appl Immunohistochem Mol Morphol; 2019; 27(10):e93-e96. PubMed ID: 28248731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical diagnosis of epithelioid mesothelioma: an update.
    Ordóñez NG
    Arch Pathol Lab Med; 2005 Nov; 129(11):1407-14. PubMed ID: 16253021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer or metastasis? An unusual case of metastatic malignant pleural mesothelioma to the breast.
    Framarino-dei-Malatesta M; Sammartino P; Derme M; Iannini I; Masselli G; Pecorella I
    World J Surg Oncol; 2015 Feb; 13():79. PubMed ID: 25849448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 2003 Aug; 27(8):1031-51. PubMed ID: 12883236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic performance of immunohistochemistry markers for malignant pleural mesothelioma diagnosis and subtypes. A systematic review and meta-analysis.
    Parra-Medina R; Castañeda-González JP; Chaves-Cabezas V; Alzate JP; Chaves JJ
    Pathol Res Pract; 2024 May; 257():155276. PubMed ID: 38603842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach.
    Ascoli V; Minelli G; Cozzi I; Romeo E; Carnovale Scalzo C; Ancona L; Forastiere F
    Pathol Res Pract; 2016 Oct; 212(10):886-892. PubMed ID: 27485167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. h-Caldesmon, a useful positive marker in the diagnosis of pleural malignant mesothelioma, epithelioid type.
    Comin CE; Dini S; Novelli L; Santi R; Asirelli G; Messerini L
    Am J Surg Pathol; 2006 Apr; 30(4):463-9. PubMed ID: 16625092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: trends in Australia and a literature review.
    Linton A; Kao S; Vardy J; Clarke S; van Zandwijk N; Klebe S
    Asia Pac J Clin Oncol; 2013 Sep; 9(3):273-9. PubMed ID: 23167246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas.
    Tot T
    Cancer; 2001 Nov; 92(10):2727-32. PubMed ID: 11745209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval.
    Riera JR; Astengo-Osuna C; Longmate JA; Battifora H
    Am J Surg Pathol; 1997 Dec; 21(12):1409-19. PubMed ID: 9414184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of thrombomodulin, calretinin, cytokeratin 5/6, D2-40 and WT-1 in a series of primary carcinomas of the lung: an immunohistochemical study in comparison with epithelioid pleural mesothelioma.
    Comin CE; Novelli L; Cavazza A; Rotellini M; Cianchi F; Messerini L
    Tumori; 2014; 100(5):559-67. PubMed ID: 25343553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.